MedPath

Sleep as a Mechanism of Change in Alcohol Use

Not Applicable
Recruiting
Conditions
Insomnia
Alcohol; Harmful Use
Interventions
Behavioral: Cognitive Behavioral Therapy for Insomnia
Registration Number
NCT06286774
Lead Sponsor
University of Missouri-Columbia
Brief Summary

This project aims to evaluate improvement of insomnia as a mechanism of improvement in alcohol use outcomes.

Detailed Description

Heavy alcohol use is prevalent in the United States and results in significant physical and psychological burden. One in 10 adults in the United States reports binge drinking on a weekly basis, and few are willing to seek mental health treatment. Thus, additional strategies are needed to engage and treat individuals at risk for alcohol-related harm. Half of those who screen positive for hazardous drinking report clinically significant symptoms of insomnia. Insomnia tends to be less stigmatized than other mental health disorders, and it is one condition for which the field has highly efficacious treatment. Thus, one potential strategy to engage individuals in mental health treatment and reduce the burden of alcohol use in the United States is to target insomnia. This project aims (1) to examine change in insomnia as a mediator of insomnia treatment effects on alcohol use outcomes and sex as a moderator of those effects and (2) to identify mechanisms linking change in insomnia to alcohol use outcomes. Adults who drink alcohol and have insomnia will be randomly assigned to Cognitive Behavioral Therapy for Insomnia (CBT-I, n=112) or waitlist control (WLC, n=112). Outcomes will be assessed weekly during treatment, at the end of the active intervention period (post-treatment), and at 1-, 3-, and 6-month follow-ups.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
256
Inclusion Criteria
  • report heavy drinking in a typical week in the past month
  • meet DSM-5 criteria for Alcohol Use Disorder
  • meet DSM-5 and research diagnostic criteria for Insomnia Disorder
Exclusion Criteria
  • ≥50 years
  • unable to provide informed consent
  • report contraindications for CBT-I (mania or seizure disorder)
  • moderate to severe sleep apnea that is untreated
  • have symptoms requiring immediate clinical attention (e.g., psychosis, suicide plan)
  • are already receiving behavioral treatment for insomnia or alcohol use

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CBT-ICognitive Behavioral Therapy for InsomniaIndividual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks.
Primary Outcome Measures
NameTimeMethod
Insomnia SymptomsChange from baseline to mid-treatment (week 4) to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups

Assessed using Insomnia Severity Index (ISI). Response options range from 0 (not at all worried) to 4 (very much worried), with total scores ranging from 0 to 28 and higher scores indicating more severe insomnia.

Drinking quantityChange from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups

Assessed using Timeline Followback and Daily Drinking Questionnaire. Typical weekly drinking quantity estimates will be summed to create a "drinks per week" total score, which will be used as our outcome variable.

Alcohol-related consequencesChange from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups

Assessed using the Drinker Inventory of Consequences (DrINC). Scores range from 0 to 120, with higher scores indicating more consequences. The common consequence subscale scores range from 0 to 18.

Secondary Outcome Measures
NameTimeMethod
Treatment willingness (alcohol)Change from baseline to post-treatment (week 6)

Assessed using a modified Treatment Willingness Scale. Participants rate their agreement with the statement that they would seek treatment for 5 medical and 5 mental health conditions if they experienced problems related to them. Willingness to seek alcohol or drug treatment is assessed on a 0-5 scale, with higher scores indicating greater willingness.

Alcohol cravingChange from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups

Assessed using the Penn Alcohol Craving Scale (PACS). PACS evaluates thoughts about drinking by assessing the duration, frequency, and intensity of such thoughts. Scores range 0-30, with higher scores indicating more severe craving.

Response inhibitionChange from baseline to post (week 6) to 3-month follow-up

Assessed using the Stroop Task. Average reaction time (RT; measured from color word/color rectangle stimuli onset until a response is made) on correct trials for each trial type (control trials, congruent trials, incongruent trials) were computed as the outcomes of interest. Higher RTs indicate worse performance.

Heartrate variabilityChange from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups

Assessed using Fitbit Charge 6. Heart-rate variability (HRV) is an indicator of activity in the autonomic nervous system that quantifies changes in intervals between heart beats. In general, HRV increases with increasing parasympathetic activity, then plateaus and decreases with increasing sympathetic activity.

Dysfunctional Beliefs and Attitudes about Sleep ScaleChange from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups

Assessed using the revised Dysfunctional Beliefs and Attitudes about Sleep Scale. Responses range from 0 to 70, with higher scores indicating more dysfunctional beliefs.

Negative emotionalityChange from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups

Negative emotionality will be assessed as a latent construct of mood, anxiety, depression, PTSD symptoms, and difficulties with emotion regulation. Changes in individual symptoms will be reported for descriptive purposes.

Working memoryChange from baseline to post (week 6) to 3-month follow-up

Assessed using the N-Back Task. The dependent measure is the proportion of correct responses (yes and no) across all four blocks. Omissions are counted as errors.

Delay discountingChange from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups

Assessed using the Monetary Choice Questionnaire (MCQ). Participants indicate if they would rather receive a smaller amount of money now or a greater amount of money in a specified amount of time (e.g., 100 days, 2 days). The MCQ is scored using a logarithmic subject-specific discount rate (k variable). Higher k values indicate a greater preference for smaller, immediate rewards over larger, delayed reward.

Alcohol to help with sleepChange from baseline to post-treatment (week 6) to 1-, 3-, and 6-month follow-ups

Assessed using daily sleep diaries. The outcome will be percentage of days using alcohol to help with sleep.

Trial Locations

Locations (1)

University of Missouri-Columbia

🇺🇸

Columbia, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath